Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor
- 16 November 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (24), 8663-8678
- https://doi.org/10.1021/jm101177s
Abstract
A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described. The compounds are potent enzyme inhibitors (IC50 values less than 100 nM), and improved activity in cell proliferation assays was achieved by modulation of polar surface area (PSA) through the introduction of novel linking groups. Employing oral pharmacokinetic studies in mice, comparing drug levels in spleen to plasma, we selected compounds that were tested for efficacy in human tumor xenograft studies based on their potential to distribute into tumor. One compound, 21r (CHR-3996), showed good oral activity in these models, including dose-related activity in a LoVo xenograft. In addition 21r showed good activity in combination with other anticancer agents in in vitro studies. On the basis of these results, 21r was nominated for clinical development.This publication has 32 references indexed in Scilit:
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsJournal of Hematology & Oncology, 2010
- Histone Deacetylase InhibitorsDrugs, 2009
- Vorinostat increases carboplatin and paclitaxel activity in non‐small cell lung cancer cellsInternational Journal of Cancer, 2009
- Rational Combinations Using HDAC InhibitorsClinical Cancer Research, 2009
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysisThe Lancet Oncology, 2008
- R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignanciesBritish Journal of Cancer, 2007
- Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinomaCancer, 2007
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitorsEuropean Journal of Medicinal Chemistry, 2005